Decentralized clinical trials are fundamentally a movement of clinical studies away from medical institutions. In this model, clinical studies are focused on bringing the clinical study directly to the participant and allowing data collection to be completed in a participant's home or local community. This paper examines the nature of decentralized clinical trials, potential benefits and risks of this new paradigm, and best practices for maintaining regulatory and Institutional Review Board (IRB) compliance.